Efficacy and safety of fenofibrate add-on therapy in patients with primary biliary cholangitis refractory to ursodeoxycholic acid: A retrospective study and updated meta-analysis
Background: Ursodeoxycholic acid (UDCA) is currently used for the treatment of primary biliary cholangitis (PBC), but some people do not respond well to UDCA. It reported that the combination of fenofibrate and UDCA can improve the clinical indices in these patients. However, more high-quality evide...
Main Authors: | Xuan Guoyun, Ding Dawei, Liu Ning, Hu Yinan, Yang Fangfang, Tian Siyuan, Sun Hao, Yang Jiaqi, Xu Ang, Guo Guanya, Chen Xi, Shang Yulong, Han Ying |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-08-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.948362/full |
Similar Items
-
Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA
by: Weijia Duan, et al.
Published: (2018-09-01) -
Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis
by: Kazufumi Dohmen, et al.
Published: (2021-10-01) -
Prevalence and effect on prognosis of sarcopenia in patients with primary biliary cholangitis
by: Jiaqi Yang, et al.
Published: (2024-02-01) -
Evaluation of the United Kingdom‐primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population
by: Mohammad Alomari, et al.
Published: (2020-04-01) -
Looking Into the Crystal Ball: Predicting Non-response to Ursodeoxycholic Acid in Primary Biliary Cholangitis
by: Vincent Zimmer, et al.
Published: (2017-02-01)